P/E ratio for Biocept (BIOC)
P/E ratio as of May 2024 (TTM): -0.0085
According to Biocept 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0085442. At the end of 2022 the company had a P/E ratio of -0.2798.
P/E ratio history for Biocept from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.2798 | -98.69% |
| 2021 | -21.3 | 763.28% |
| 2020 | -2.47 | 1122.28% |
| 2019 | -0.2018 | 131.85% |
| 2018 | -0.0870 | -89.94% |
| 2017 | -0.8654 | 135.13% |
| 2016 | -0.3680 | -75.9% |
| 2015 | -1.53 | 120.62% |
| 2014 | -0.6921 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Veracyte VCYT | -48.9 | 572,510.66% | 🇺🇸 USA |
 Exact Sciences EXAS | -37.4 | 437,979.63% | 🇺🇸 USA |
 Myriad Genetics MYGN | -6.44 | 75,243.51% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.